Susan Bates

Scientist Doctor Mom

[Susan Bates @susanebates]

@realbowtiedoc @OncJournal @crisbergerot @montypal @Brxmom_07 @DarcyBurbage @PallOncCoP @jatwanikaran Thank you @realbowtiedoc!! It was a terrific concept and great way to meet some new and talented investigators, and to highlight a paper from @OncJournal @Brxmom_07

[Susan Bates @susanebates]

@crisbergerot @Brxmom_07 @realbowtiedoc @jatwanikaran @montypal @OncJournal @DarcyBurbage @Linda_E_Carlson @AmDTx_official Is it usable now for patients not on clinical trials? #TOeJC

[Susan Bates @susanebates]

@crisbergerot @realbowtiedoc @jatwanikaran @montypal @Brxmom_07 @OncJournal @DarcyBurbage #TOeJC But if you had to choose just one to add to a study mainly focused on a novel treatment, what would you choose. Which worked best in your trial @crisbergerot ?

[Susan Bates @susanebates]

@crisbergerot @realbowtiedoc @jatwanikaran @montypal @Brxmom_07 @OncJournal @DarcyBurbage hi - I think I was posting the question incorrectly - but my apologies if this is a repeat. How do we best measure distress? In the clinic? In clinical trials? #TOeJC,

[Susan Bates @susanebates]

@realbowtiedoc @jatwanikaran @crisbergerot @montypal @Brxmom_07 @OncJournal @DarcyBurbage Can we come back to the question of how best to measure distress in research setting, or a standard of care setting? @realbowtiedoc

[Susan Bates @susanebates]

@jatwanikaran I'm still not seeing how this is measured, and whether you can measure the "harm" of distress. We intuitively know a distressed patient is not a good thing but if we can't easily measure it, we have more difficulty knowing what works and doesn't work to improve things.

[Susan Bates @susanebates]

@jatwanikaran How is it best measured, according to the study??

[Susan Bates @susanebates]

Which scale most accurately measured distress in this study?

[karan jatwani @jatwanikaran]

🚨 What is Distress in Cancer Care? 🚨
Cancer Distress 😟 is psychological/social/spiritual pain. 1 in 4 (20%)-->up to 80% impacted. Screen it! 🩺 The 6th Vital Sign!
#DistressScreening #PallOnc #TOeJC
https://t.co/ff0zBWxD8J

[Susan Bates @susanebates]

This is our first ever OUP eJournal Club! We are anxious to ehear your thoughts on this study.

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

@realbowtiedoc @lindacarlson @ASCO @Integrativeonc Absolutely agree — mindfulness-based interventions like #MBCR have shown meaningful benefits for people with cancer. Expanding access, particularly in #LMICs, remains a crucial next step. #TOeJC @OncJournal
@Linda_E_Carlson @AmDTx_official

[Dr Joseph McCollom DO @realbowtiedoc]

We are thrilled to share a recent publication from @OncJournal Feasibility and acceptability of a mindfulness app-based intervention among patients with metastatic renal cell carcinoma: a multinational study
🔗: https://t.co/S4RvXvzG10 #TOeJC

[Susan Bates @susanebates]

@OncJournal @realbowtiedoc @crisbergerot @montypal @jatwanikaran As I understand it, this is going to be a look at distress in patients undergoing cancer treatment.

[Susan Bates @susanebates]

@OncJournal @realbowtiedoc @crisbergerot @montypal @jatwanikaran Exited to ehear the discussion on the recent paper in The Oncologist "Feasibility and acceptability of a mindfulness app-based intervention among patients with metastatic renal cell carcinoma: a multinational study"!!!

[FDA Oncology @FDAOncology]

OCE's @GautamMehtaMD and colleagues summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki—the first targeted treatment option for patients with HER2-mutated non-small cell lung cancer - via @OncJournal
https://t.co/lqWTdIbNwq

#OCEPublications #lcsm #NSCLC

[Susan Bates @susanebates]

@OUPMedicine @OncJournal Excited to meet people. But! Exhibit Hall still under construction. So no meeting today. Will also be there Sunday at 12:30 pm! Hope to see you there. Booth 10076

[FDA Oncology @FDAOncology]

Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials - via @OncJournal. https://t.co/7XgobG89t3
#OCEPublications

[The Oncologist @OncJournal]

Unraveling the Link: MUTYH mutations drive higher KRAS G12C prevalence, heightened tumor mutational burden, and unique mutational signatures across cancers. @fred_hirsch #MolecularBiology #Research https://t.co/FgYTuCnuTZ

[Society for Translational Oncology @SocTransOnc]

Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study https://t.co/4xONb4AweX

[Susan Bates @susanebates]

@OncJournal This Commentary sheds light on a lot of the concerns about Hospice that our patients have regarding “access to high quality hospice care….”

[Susan Bates @susanebates]

@MDRoeland @OncJournal @ASCO @MASCC Thank you for highlighting this paper in @OncJournal. This is an understudied source of misery for many patients with #cancer. We've published on this before. https://t.co/3cZ4Fs1T5S; https://t.co/ZuxtJJ5gaY

[EORTC @EORTC]

📚 🔬 Thrilled to share a new EORTC publication on @OncJournal:

"#QualityOfLife in Male #BreastCancer: Prospective Study of the International #MaleBreastCancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)"

👉 https://t.co/KROb3ywueR

#CancerResearch #ClinicalTrials #Oncology